Anal Cancer: Focus on HIV-positive patients in the HAART era

Current HIV Research

Volumn 9, Issue 2, 2011, Pages 70-81

  Zanet, Ernesto ^a,b   Berretta, Massimiliano ^b   Martellotta, Ferdinando ^b   Cacopardo, Bruno ^a   Fisichella, Rossella ^a   Tavio, Marcello ^c   Berretta, Salvatore ^a   Tirelli, Umberto ^b  

^a UNIVERSITY OF CATANIA   (Italy)

^b CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^c Division of Infectious Diseases of Ancona   (Italy)

Author keywords

AIDS; Anal cancer; HAART; HIV; HPV; Treatment

Indexed keywords

ANTIRETROVIRUS AGENT; CANCER VACCINE; CISPLATIN; FLUOROURACIL; IMIQUIMOD; LIQUID NITROGEN; MITOMYCIN C; PODOPHYLLOTOXIN; TOPICAL AGENT; TRICHLOROACETIC ACID; WART VIRUS VACCINE;

ACUTE TOXICITY; ANAL INTRAEPITHELIAL NEOPLASIA; ANUS CANCER; ANUS TUMOR; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER INHIBITION; CANCER INVASION; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CARCINOGENESIS; CAUTERIZATION; CD4 CD8 RATIO; CD4 LYMPHOCYTE COUNT; CHRONIC TOXICITY; COLON CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONDYLOMA ACUMINATUM; CONTINUOUS INFUSION; CROSS PROTECTION; DERMATITIS; DESQUAMATION; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DISTANT METASTASIS; EXTERNAL BEAM RADIOTHERAPY; FOCAL EPITHELIUM HYPERPLASIA; GASTROINTESTINAL TOXICITY; HIGH RESOLUTION ENDOSCOPY; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOPATHOLOGY; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 35; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN PAPILLOMAVIRUS TYPE 59; IMMUNOSUPPRESSIVE TREATMENT; INCONTINENCE; INVASIVE PROCEDURE; LEUKOPENIA; LUNG EMBOLISM; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NONHUMAN; OROPHARYNX CARCINOMA; OVERALL SURVIVAL; PATHOLOGICAL ANATOMY; POSITRON EMISSION TOMOGRAPHY; PROCTITIS; RECTUM CARCINOMA; RECTUM HEMORRHAGE; RECURRENCE RISK; RISK REDUCTION; SEXUAL TRANSMISSION; SEXUALLY TRANSMITTED DISEASE; SIDE EFFECT; SKIN TOXICITY; SKIN ULCER; SQUAMOUS CELL CARCINOMA; STOMACH CANCER; SURVIVAL RATE; THROMBOCYTOPENIA; TOPICAL TREATMENT; TUMOR ABLATION; VERRUCA PLANA JUVENILIS; VERRUCA PLANTARIS; VERRUCA VULGARIS; VERRUCOUS CARCINOMA; VIRUS LOAD; VIRUS REPLICATION; VIRUS TYPING; WART VIRUS;

EID: 79953293151     PISSN: 1570162X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016211795569087     Document Type: Article

References (77)

1. Deans GT, McAleer JJ, Spence RA. Malignant anal tumours. Br J Surg 1994; 81: 500-558.
2. Ryan DP, Compton CC, Mayer RJ. Carcinoma of the anal canal. N Eng J Med 2000; 342: 792-800.
3. Patel P, Hanson DL, Sullivan PS, et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med 2008; 148: 728-736.
4. Crum-Cianflone NF, Hullsiek KH, Marconi VC, et al. Anal cancer among HIV-infected persons: HAART is not slowing rising incidence. AIDS 2010; 24: 535-543.
5. D'Souza G, Wiley DJ, Li X, et al. Incidence and epidemiology of anal cancer in the Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr 2008; 48: 491-499.
6. Piketty C, Selinger-Leneman H, Grabar S, et al. Marked increase in the incidence of invasive anal cancer among HIV-infected patients despite treatment with combination antiretroviral therapy AIDS 2008; 22: 1203-1211.
7. Maggard, MA, Beanes SR, Ko CY. Anal canal cancer: a population-based reappraisal. Dis Colon Rectum 2003; 46: 1517-1523.
8. Daling JR, Weiss NS, Hislop TG, et al. Sexual practises, sexually transmitted diseases, and the incidence of anal cancer. N Eng J Med 1987; 317: 973-977.
9. Frisch M, Glimelius B, van den Brule AJ, et al. Sexually transmitted infection as a cause of anal cancer. N Eng J Med 1997; 337: 1350-1358.
10. Melbye M, Sprogel P. Aetiological parallel between anal cancer and cervical cancer. Lancet 1991; 338: 657-659.
11. Frisch M, Fenger C, van den Brule AJ, et al. Variants of squamous cell carcinoma of the anal canal and perianal skin and their relation to human papillomaviruses. Cancer Res 1999; 59: 753-757.
12. Daling JR, Madeleine MM, Johnson LG, et al. Human papillomavirus, smoking and sexual practises in the aetiology of anal cancer. Cancer 2004; 101: 270-80.
13. Carter JJ, Madeleine MM, Shera K, et al. Human papillomavirus 16 and 18 L1 serology compared across anogenital cancer sites. Cancer Res 2001; 61: 1934-1940.
14. Palefsky JM. Human papillomavirus infection in HIV-infected persons. Top HIV Med 2007; 15: 130-133.
15. Zbar AP, Fenger C, Efron J, et al. The pathology and molecular biology of anal intraepithelial neoplasia: comparisons with cervical and vulvar intraepithelial carcinoma. Int J Colorectal Dis 2002; 17: 203-215.
16. Palefsky JM, Holly EA, Ralston ML, et al. High incidence of anal high-grade squamous intra-epithelial lesions among HIV-positive and HIV-negative homosexual and bisexual men. AIDS 1998; 12: 495-503.
17. Hoots BE, Palefsky JM, Pimenta JM, Smith JS. Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions. Int J Cancer 2009; 124: 2375-2383.
18. De Pokomandy A, Rouleau D, Ghattas G, et al. Prevalence, clearance, and incidence of anal human papillomavirus infection in HIV-infected men: the HIPVIRG cohort study. J Infect Dis 2009; 199: 965-973.
19. Evander M, Edlund K, Gustafsson A, et al. Human papillomavirus is transient in young women: a population-based cohort study. J Infect Dis 1995; 171: 1026-1030.
20. Cullen AP, Reid R, Campion M, Lörincz AT. Analysis of the physical state of different human papillomavirus DNAs in intraepithelial and invasive cervical neoplasm. J Virol 1991; 65: 606-612.
21. Hopman AH, Smedts F, Dignef W, et al. Transition of high-grade cervical intraepithelial neoplasia to micro-invasive carcinoma is characterized by integration of HPV 16/18 and numerical chromosome abnormalities. J Pathol 2004; 202: 23-33.
22. Graham DA, Herrington CS. HPV-16 E2 gene disruption and subsequent variation in CIN 3 lesions and invasive squamous cell carcinomas of the cervix: relation to numerical chromosome abnormalities. J Clin Pathol 2000; 53: 201-206.
23. Werness BA, Levine AJ, Howley PM. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 1990; 248: 76-79.
24. Dyson N, Howley PM, Münger K, Harlow E. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 1989; 243: 934-947.
25. Michor F, Iwasa Y, Vogelstein B, Lengauer C, Nowak MA. Can chromosomal instability initiate tumorigenesis? Semin Cancer Biol 2005; 15: 43-49.
26. Haga T, Kim SH, Jensen RH, Darragh T, Palefsky JM. Detection of genetic changes in anal intraepithelial neoplasia (AIN) of HIV-positive and HIV-negative men. J Acquir Immune Defic Syndr 2001; 26: 256-262.
27. Palefsky JM, Holly EA, Hogeboom CJ, et al. Virologic, immunologic, and clinical parameters in the incidence and progression of anal squamous intraepithelial lesions in HIV-positive and HIV-negative homosexual men. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 17: 314-319.
28. Frisch M, Biggar RJ, Goedert JJ. Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst 2000; 92: 1500-1510.
29. Penn I. Cancers of the anogenital region in renal transplant recipients. Analysis of 65 cases. Cancer 1986; 58: 611-16.
30. Arends MJ, Benton EC, McLaren KM, et al. Renal allograft recipients with high susceptibility to cutaneous malignancy have an increased prevalence of human papillomavirus DNA in skin tumours and a greater risk of anogenital malignancy. Br J Cancer 1997; 75: 722-728.
31. Palefsky JM, Holly EA. Immunosuppression and co-infection with HIV. J Natl Cancer Inst Monogr 2003; 31: 41-46.
32. Gervaz P, Efron J, Poza AA, et al. Loss of heterozygosity and HIV infection in patients with anal squamous-cell carcinoma. Dis Colon Rectum 2001; 44: 1503-1508.
33. Chin-Hong PV, Palefsky JM. Natural history and clinical management of anal human papillomavirus disease in men and women infected with human immunodeficiency virus. Clin Infect Dis 2002; 35: 1127-1134.
34. Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002; 287: 2114-2119.
35. Chiao EY, Giordano TP, Palefsky JM, Tyring S, El Serag H. Screening HIV-infected individuals for anal cancer precursor lesions: a systematic review. Clin Infect Dis 2006; 43: 223-233.
36. Tanum G, Tveit K, Karlsen KO. Diagnosis of anal carcinoma -doctor's finger still the best? Oncology 1991; 48: 383-386.
37. th ed. Philadelphia: Lippincott-Raven Publishers; 1997.
38. Trautmann TG, Zuger JH. Positron emission tomography for pre-treatment staging and post-treatment evaluation in cancer of the anal canal. Mol Imaging Biol 2005; 7: 309-313.
39. Cotter SE, Grigsby PW, Siegel BA, et al. FDG-PET/CT in the evaluation of anal carcinoma. Int J Radiat Oncol Biol Phys 2006; 65: 720-725.
40. Palefsky JM, Holly EA, Ralston ML, et al. Effect of highly active antiretroviral therapy on the natural history of anal squamous intraepithelial lesions and anal human papillomavirus infection. J Acquir Immune Defic Syndr 2001; 28: 422-428.
41. Fox PA, Seet JE, Stebbing J, et al. The value of anal cytology and human papillomavirus typing in the detection of anal intraepithelial neoplasia: a review of cases from an anoscopy clinic. Sex Transm Inf 2005; 81: 142-146.
42. Chin-Hong PV, Palefsky JM. Human papillomavirus anogenital disease in HIV-infected individuals. Dermatol Ther 2005; 18: 67-76.
43. Miles W. Pathology of spread of cancer of rectum and its bearing upon surgery of cancerous rectum. Surg Gynecol Obstet 1931; 52: 350-359.
44. Nigro ND, Vaitkevicius V, Considine B. Combined therapy for cancer of the anal canal: a preliminary report. Dis Colon rectum 1974; 17: 354-356.
45. Fuchshuber PR, Rodriguez-Bigas M, Weber T, Petrelli NJ. Anal cancer and perianal epidermoid cancers. J Am Coll Surg 1997; 185: 494-505.
46. UKCCCR Anal Cancer Trial Working Group. Epidermoid anal cancer: results from the UKCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and Mitomycin. Lancet 1993; 348: 1049-1054.
47. Bartelink H, Roelofsen F, Eschwege F, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomised trial of the European Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol 1997; 15: 2040-2049.
48. Martenson JA, Lipsitz SR, Wagner H Jr, et al. Initial results of phase II trial of high dose radiation therapy, 5-fluorouracil, and Cisplatinum for patients with anal cancer (E4292): an Eastern Cooperative oncology Group Study. Int J Radiat Oncol Biol Phys 1996; 35: 745-749.
49. Holland JM, Swift PS. Tolerance of patients with human immunodeficiency virus and anal carcinoma to treatment with combined chemotherapy and radiation therapy. Radiology 1994; 193: 251-254.
50. Peddada AV, Smith DE, Rao AR, Frost DB, Kagan AR. Chemotherapy and low-dose radiotherapy in the treatment of HIV-infected patients with carcinoma of the anal cancer. Int J Radiat Oncol Biol Phys 1997; 37: 1101-1105.
51. Nigro ND, Vaitkevicius VK. Combined therapy for cancer of the anal cancer. Dis Colon Rectum 1991; 34: 482-486.
52. Hoffman R, Welton ML, Klencke B, Weinberg V, Krieg R. The significance of pretreatment CD4 count on the outcome and treatment tolerance of HIV-positive patients with anal cancer. Int J Radiat Oncol Biol Phys 1999; 44: 127-131.
53. Wexler A, Berson AM, Goldstone SE, et al. Invasive anal squamous-cell carcinoma in the HIV-positive patient: outcome in the era of highly active antiretroviral therapy. Dis Colon Rectum 2008; 51: 73-81.
54. Stadler RF, Gregorcyk SG, Euhus DM, Place RJ, Huber PJ, Simmang CL. Outcome of HIV-infected patients with invasive squamous-cell carcinoma of anal canal in the era of highly active antiretroviral therapy. Dis Colon Rectum 2004; 47: 1305-1309.
55. Cleator S, Fife K, Nelson M, Gazzard B, Phillips R, Bower M. Treatment of HIV-associated invasive anal cancer with combined chemoradiation. Eur J Cancer 2000; 36: 754-758.
56. Chiao EY, Giordano TP, Richardson P, El-Serag HB. Human Immunodeficiency Virus-associated squamous cell cancer of the anus: epidemiology and outcomes in the highly active antiretroviral therapy era. J Clin Oncol 2008; 26: 474-479.
57. Blazy A, Hennequin C, Gornet JM, et al. Anal carcinomas in HIV-positive patients: high dose chemoradiotherapy is feasible in the era of highly active antiretroviral therapy. Dis Colon Rectum 2005; 48: 1176-1781.
58. Seo Y, Kinsella MT, Reynolds HL, Chipman G, Remick SC, Kinsella TJ. Outcomes of chemoradiotherapy with 5-fluorouracil and Mitomycin C for anal cancer in immunocompetent versus immunodeficient patients. Int J Radiat Oncol Biol Phys 2009; 75: 143-149.
59. Fraunholz I, Weiss C, Eberlein K, et al. Concurrent chemoradiotherapy with 5-fluorouracil and mitomycin c for invasive anal carcinoma in human immunodeficiency virus-positive patients receiving highly active antiretroviral therapy. Int J Radiat Oncol Biol Phys 2010; 76: 1425-1432.
60. Abramowitz L, Mathieu N, Roudot-Thoraval F, et al. Epidermoid anal cancer prognosis comparison among HIV+ and HIV-patients. Aliment Pharmacol Ther 2009; 30: 414-421.
61. Salama JK, Mell LK, Schomas DA, et al. Concurrent chemotherapy and intensity-modulated radiation therapy for anal cancer patients: a multicenter experience. J Clin Oncol 2007; 25: 4581-4586.
62. Oehler-Jänne C, Seifert B, Lütolf UM, Ciernik IF. Local tumor control and toxicity in HIV-associated anal carcinoma treated with radiotherapy in the era of antiretroviral therapy. Radiat Oncol 2006; 1: 29.
63. Oehler-Jänne C, Huguet F, Provencher S, et al. HIV-specific differences in outcome of squamous cell carcinoma of the anal canal: a Multicentric cohort study of HIV-positive patients receiving highly active antiretroviral therapy. J Clin Oncol 2008; 26: 2550-2557.
64. Hogg ME, Popowich DA, Wang EC et al. HIV and anal cancer outcomes: a single institution's experience. Dis Colon Rectum 2009; 52: 891-897.
65. Kreuter A, Potthoff A, Brockmeyer NH, et al. Anal carcinoma in HIV-positive men: results of a prospective study from Germany. Br J Dermatol 2010 [Epub ahead of print].
66. Palefsky JM, Gillison ML, Strickler HD. Chapter 16: HPV vaccines in immunocompromised women and men. Vaccine 2006; 24: S140-S146.
67. Stanley M, Lowy DR, Frazer I. Prophylactic HPV vaccines: underlying mechanisms. Vaccine 2006; 24: S106-S113.
68. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Eng J Med 2007; 356: 1928-1943.
69. Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER; Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices (ACIP). Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practises (ACIP). MMWR Recomm Rep 2007; 56: 1-24.
70. Sawaya GF, Smith-McCune K. HPV vaccination - more answers, more questions. N Eng J Med 2007; 356: 1991-1993.
71. Haug CJ. Human papillomavirus vaccination - reasons for caution. N Eng J Med 2008: 359: 861-862.
72. Brown DR, Kjaer SK, Sigurdsson K, et al. The impact of quadrivalent human papillomavirus (HPV; Types 6, 11, 16 and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naïve women aged 16-26 years. J Infect Dis 2009; 199: 926-935.
73. Wheeler CM, Kjaer SK, Sigurdsson K, et al. The impact of quadrivalent human papillomavirus (HPV; Types 6, 11, 16 and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis 2009; 199: 936-944.
74. Goldstein MA. Human papillomavirus vaccine in males. N Eng J Med 2008; 359: 863-864.
75. Baden LR, Curfman GD, Morrissey S, Drazen JM. Human papillomavirus vaccine - opportunity and challenge. N Eng J Med 2007; 356: 1990-1991.
76. Geretti AM, Doyle T. Immunization for HIV-positive individuals. Curr Opin Infect Dis 2010; 23: 32-38.
77. Anderson JS, Hoy J, Hillman R, et al. A randomized, placebo-controlled, dose -escalation study to determine the safety, tolerability, and immunogenity of an HPV-16 therapeutic vaccine in HIV-positive participants with oncogenic HPV infection of the anus. J Acquir Immune Defic Syndr 2009; 52: 371-381.